Protein misfolding in the late-onset neurodegenerative diseases: Common themes and the unique case of amyotrophic lateral sclerosis

Proteins: Structure, Function and Bioinformatics

Volumn 81, Issue 8, 2013, Pages 1285-1303

  Mulligan, Vikram Khipple ^a   Chakrabartty, Avijit ^b,c,d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Department of Biochemistry ^*  (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Ageing; Alzheimer's disease; Amyloid; Folding kinetics; Folding pathways; Huntington's disease; Parkinson's disease; Prion disease; Protein aggregation; Senescence

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; PRION PROTEIN;

ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; DIFFERENTIAL SCANNING CALORIMETRY; DISEASE COURSE; DOMINANT INHERITANCE; FRAMESHIFT MUTATION; GRAY MATTER; HUMAN; HUNTINGTON CHOREA; LATENT PERIOD; LIFE EXPECTANCY; METAL BINDING; MUTATION; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; ONSET AGE; OXIDATIVE STRESS; PARKINSON DISEASE; PHENOTYPE; POINT MUTATION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN CROSS LINKING; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN MISFOLDING; PROTEIN PROTEIN INTERACTION; PROTEIN QUATERNARY STRUCTURE; PROTEIN STABILITY; PROTEIN SUBUNIT; PROTEIN UNFOLDING; QUALITY OF LIFE; REVIEW; RISK FACTOR;

AGEING; ALZHEIMER'S DISEASE; AMYLOID; FOLDING KINETICS; FOLDING PATHWAYS; HUNTINGTON'S DISEASE; PARKINSON'S DISEASE; PRION DISEASE; PROTEIN AGGREGATION; SENESCENCE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; HUMANS; MODELS, MOLECULAR; MUTATION; NEURODEGENERATIVE DISEASES; PROTEIN FOLDING; SUPEROXIDE DISMUTASE;

EID: 84880703265     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.24285     Document Type: Review

References (241)

1. Oeppen J, Vaupel JW. Broken limits to life expectancy. Science 2002;296:1029-1031.
2. World Health Statistics 2011. Geneva, Switzerland: WHO Department of Health Statistics and Informatics; 2011. pp 170.
3. Moss WJ, Griffin DE. Measles. Lancet 2012;379:153-164.
4. Measles vaccines: WHO position paper. Wkly Epidemiol Rec 2009;84:349-360.
5. Schreiber A, Hershman G. Non-HIV viral infections of the salivary glands. Oral Maxillofac Surg Clin N Am 2009;21:331-338.
6. Hviid A, Rubin S, Muhlemann K. Mumps. Lancet 2008;371:932-944.
7. Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol 2010;172:1213-1229.
8. Lane JM. Mass vaccination and surveillance/containment in the eradication of smallpox. Curr Topics Microbiol Immunol 2006;304:17-29.
9. Vazquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001;344:955-960.
10. Marin M, Zhang JX, Seward JF. Near elimination of varicella deaths in the US after implementation of the vaccination program. Pediatrics 2011;128:214-220.
11. Clark NM, Lynch JP, III. Influenza: epidemiology, clinical features, therapy, and prevention. Semin Respir Crit Care Med 2011;32:373-392.
12. Friede M, Palkonyay L, Alfonso C, Pervikov Y, Torelli G, Wood D, Kieny MP. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. Vaccine 2011;29(Suppl 1):A2-A7.
13. Merle CS, Cunha SS, Rodrigues LC. BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. Expert Rev Vaccines 2010;9:209-222.
14. Rodrigues LC, Lockwood D. Leprosy now: epidemiology, progress, challenges, and research gaps. Lancet Infect Dis 2011;11:464-470.
15. Clemens JD. Vaccines in the time of cholera. Proc Natl Acad Sci USA 2011;108:8529-8530.
16. Sur D, Lopez AL, Kanungo S, Paisley A, Manna B, Ali M, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Rao R, Nguyen TV, Donner A, Ganguly NK, Nair GB, Bhattacharya SK, Clemens JD. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1694-1702.
17. Charles RC, Ryan ET. Cholera in the 21st century. Curr Opin Infect Dis 2011;24:472-477.
18. Collins JJ. The contribution of medical measures to the decline of mortality from respiratory tuberculosis: an age-period-cohort model. Demography 1982;19:409-427.
19. Onozaki I, Raviglione M. Stopping tuberculosis in the 21st century: goals and strategies. Respirology 2010;15:32-43.
20. Atre SR, Rangan SG, Shetty VP, Gaikwad N, Mistry NF. Perceptions, health seeking behaviour and access to diagnosis and treatment initiation among previously undetected leprosy cases in rural Maharashtra, India. Lepr Rev 2011;82:222-234.
21. Banta HD. Global issues on the agenda at the World Health Assembly: discussion of HIV/AIDS, leprosy, access to drugs. JAMA 2001;286:29-30.
22. Keshavjee S, Farmer PE. Time to put boots on the ground: making universal access to MDR-TB treatment a reality. Int J Tuberc Lung Dis 2010;14:1222-1225.
23. Park PH, Magut C, Gardner A, O'Yiengo D O, Kamle L, Langat BK, Buziba NG, Carter EJ. Increasing access to the MDR-TB surveillance programme through a collaborative model in western Kenya. Tropical Med Int Health 2012;17:374-379.
24. Lienhardt C, Vernon A, Raviglione MC. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Curr Opin Pulm Med 2010;16:186-193.
25. Price DL. Aging of the brain and dementia of the Alzheimer type. In: Kandel ER, Schwartz JH, Jessell TM, editors. Principles of neural science, 4th ed. New York: McGraw-Hill; 2000. pp 1149-1161.
26. Leading Causes of Death in Canada, 2008: StatsCan publication 84-215-X, Vol. 2011: Statistics Canada; 2011.
27. Leading Causes of Death in Canada, 2009: StatsCan publication 84-215-XWE, Vol. 2012: Statistics Canada; 2012.
28. Murphy SLX, J., Kochanek KD. Deaths: preliminary data for 2010. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics. Natl Vital Stat Syst 2012;60:1-68.
29. Minino AM, Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2008. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics. Natl Vital Stat Syst 2011;59:1-126.
30. Reddel RR. A reassessment of the telomere hypothesis of senescence. Bioessays 1998;20:977-984.
31. Hamill RW, Markesbery WR, McDaniel K, Coleman PD. Characterization of brain samples in studies of aging, Alzheimer's, and other neurodegenerative diseases. Neurobiol Aging 1993;14:539-545.
32. Novak MJ, Tabrizi SJ. Huntington's disease: clinical presentation and treatment. Int Rev Neurobiol 2011;98:297-323.
33. Saxena S, Caroni P. Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron 2011;71:35-48.
34. Ince PG, Lowe J, Shaw PJ. Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology. Neuropathol Appl Neurobiol 1998;24:104-117.
35. Mitchell JD, Borasio GD. Amyotrophic lateral sclerosis. Lancet 2007;369:2031-2041.
36. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics. Natl Vital Stat Syst 2009;57:1-134.
37. Lees AJ. L-dopa treatment and Parkinson's disease. Q J Med 1986;59:535-547.
38. Foltynie T, Michell AW, Barker RA. Parkinson's disease: what is it? what causes it? and how can it be cured? In: Smith HJ, Simons C, Sewell RDE, editors. Protein misfolding in neurodegenerative diseases. Boca Raton, FL: CRC Press; 2008. pp 381-414.
39. Small DH. Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: do we need new inhibitors? Expert Opin Emerg Drugs 2005;10:817-825.
40. Cheah BC, Vucic S, Krishnan AV, Kiernan MC. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem 2010;17:1942-1199.
41. Molinuevo JL, Llado A, Rami L. Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias. Am J Alzheimers Dis Other Demen 2005;20:77-85.
42. Bellingham MC. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci Therap 2011;17:4-31.
43. Mitchell JD, O'Brien M R, Joshi M. Audit of outcomes in motor neuron disease (MND) patients treated with riluzole. Amyotroph Lateral Scler 2006;7:67-71.
44. Herrmann N, Chau SA, Kircanski I, Lanctot KL. Current and emerging drug treatment options for Alzheimer's disease: a systematic review. Drugs 2011;71:2031-2065.
45. Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 2011;68:991-998.
46. Petersen RC. New clinical criteria for the Alzheimer's disease spectrum. Minnesota Med 2012;95:42-45.
47. Albanese A. Diagnostic criteria for Parkinson's disease. Neurol Sci 2003;24(Suppl 1):S23-S26.
48. Blonder LX, Slevin JT. Emotional dysfunction in Parkinson's disease. Behav Neurol 2011;24:201-217.
49. Brown K, Mastrianni JA. The prion diseases. J Geriatr Psychiatry Neurol 2010;23:277-298.
50. Prusiner SB. The prion diseases. Brain Pathol 1998;8:499-513.
51. Barash JA. Clinical features of sporadic fatal insomnia. Rev Neurol Dis 2009;6:E87-E93.
52. Lugaresi E, Tobler I, Gambetti P, Montagna P. The pathophysiology of fatal familial insomnia. Brain Pathol 1998;8:521-526.
53. Medori R, Tritschler HJ, LeBlanc A, Villare F, Manetto V, Chen HY, Xue R, Leal S, Montagna P, Cortelli P, Tinuper P, Avoni P, Mochi M, Baruzzi A, Hauw JJ, Ott J, Lugaresi E, Autilio-Gambetti L, Gambetti P. Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene. N Engl J Med 1992;326:444-449.
54. Reiner A, Dragatsis I, Dietrich P. Genetics and neuropathology of Huntington's disease. Int Rev Neurobiol 2011;98:325-372.
55. Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langston JW. Head injury and Parkinson's disease risk in twins. Ann Neurol 2006;60:65-72.
56. Lai BC, Marion SA, Teschke K, Tsui JK. Occupational and environmental risk factors for Parkinson's disease. Parkinsonism Relat Disord 2002;8:297-309.
57. Liu B, Gao HM, Hong JS. Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ Health Perspect 2003;111:1065-1073.
58. Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009;18:R48-R59.
59. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
60. Rogaeva E. The solved and unsolved mysteries of the genetics of early-onset Alzheimer's disease. Neuromol Med 2002;2:1-10.
61. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin JF, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A, Sanseau P, Polinsky RJ, Wasco W, Da Silva HA, Haines JL, Perkicak-Vance MA, Tanzi RE, Roses AD, Fraser PE, Rommens JM, St George-Hyslop PH. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995;375:754-760.
62. Majoor-Krakauer D, Willems PJ, Hofman A. Genetic epidemiology of amyotrophic lateral sclerosis. Clin Genet 2003;63:83-101.
63. Rakhit R, Chakrabartty A. Structure, folding, and misfolding of Cu, Zn superoxide dismutase in amyotrophic lateral sclerosis. Biochim Biophys Acta 2006;1762:1025-1037.
64. Prusiner SB, DeArmond SJ. Molecular biology and pathology of scrapie and the prion diseases of humans. Brain Pathol 1991;1:297-310.
65. Prusiner SB. Scrapie prions. Annu Rev Microbiol 1989;43:345-374.
66. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK, Litvan I. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009;8:1150-1157.
67. Rahimi F, Bitan G. Overview of fibrillar and oligomeric assemblies of amyloidogenic proteins. In: Rahimi F, Bitan G, editors. Non-fibrillar amyloidogenic protein assemblies-common cytotoxins underlying degenerative diseases. Dordrecht, The Netherlands: Springer; 2012. pp 1-36.
68. Munch C, Bertolotti A. Propagation of the prion phenomenon: beyond the seeding principle. J Mol Biol 2012;421:491-498.
69. Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. J Clin Investig 2005;115:1449-1457.
70. Bates G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet 2003;361:1642-1644.
71. Ignatova Z, Gierasch LM. Extended polyglutamine tracts cause aggregation and structural perturbation of an adjacent beta barrel protein. J Biol Chem 2006;281:12959-12967.
72. Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St George Hyslop P, Selkoe DJ. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 1997;3:67-72.
73. Bateman DA, Chakrabartty A. Interactions of Alzheimer amyloid peptides with cultured cells and brain tissue, and their biological consequences. Biopolymers 2004;76:4-14.
74. Gorman PM, Chakrabartty A. Alzheimer beta-amyloid peptides: structures of amyloid fibrils and alternate aggregation products. Biopolymers 2001;60:381-394.
75. Morales R, Duran-Aniotz CA, Soto C. Role of prion protein oligomers in the pathogenesis of transmissible spongiform encephalopathies. In: Rahimi F, Bitan G, editors. Non-fibrillar Amyloidogenic Protein Assemblies -- Common Cytotoxins Underlying Degenerative Diseases. Dordrecht, The Netherlands: Springer; 2012. pp 319-335.
76. Fawzi NL, Phillips AH, Ruscio JZ, Doucleff M, Wemmer DE, Head-Gordon T. Structure and dynamics of the Abeta(21-30) peptide from the interplay of NMR experiments and molecular simulations. J Am Chem Soc 2008;130:6145-6158.
77. Vivekanandan S, Brender JR, Lee SY, Ramamoorthy A. A partially folded structure of amyloid-beta(1-40) in an aqueous environment. Biochem Biophys Res Commun 2011;411:312-316.
78. Dobson CM. Principles of protein folding, misfolding and aggregation. Semin Cell Dev Biol 2004;15:3-16.
79. Naeem A, Fazili NA. Defective protein folding and aggregation as the basis of neurodegenerative diseases: the darker aspect of proteins. Cell Biochem Biophys 2011;61:237-250.
80. Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006;443:780-786.
81. Ying Z, Wang H, Wang G. The Ubiquitin Proteasome System as a Potential Target for the Treatment of Neurodegenerative Diseases. Current Pharma Design, in press.
82. Meredith SC. Protein denaturation and aggregation: cellular responses to denatured and aggregated proteins. Ann NY Acad Sci 2005;1066:181-221.
83. Milanesi L, Sheynis T, Xue WF, Orlova EV, Hellewell AL, Jelinek R, Hewitt EW, Radford SE, Saibil HR. Direct three-dimensional visualization of membrane disruption by amyloid fibrils. Proc Natl Acad Sci USA 2012;109:20455-20460.
84. Williams TL, Johnson BR, Urbanc B, Jenkins AT, Connell SD, Serpell LC. Abeta42 oligomers, but not fibrils, simultaneously bind to and cause damage to ganglioside-containing lipid membranes. Biochem J 2011;439:67-77.
85. Chung J, Yang H, de Beus MD, Ryu CY, Cho K, Colon W. Cu/Zn superoxide dismutase can form pore-like structures. Biochem Biophys Res Commun 2003;312:873-876.
86. Rambold AS, Miesbauer M, Rapaport D, Bartke T, Baier M, Winklhofer KF, Tatzelt J. Association of Bcl-2 with misfolded prion protein is linked to the toxic potential of cytosolic PrP. Mol Biol Cell 2006;17:3356-3368.
87. Chai Y, Shao J, Miller VM, Williams A, Paulson HL. Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis. Proc Natl Acad Sci USA 2002;99:9310-9315.
88. Faes L, Callewaert G. Mitochondrial dysfunction in familial amyotrophic lateral sclerosis. J Bioenerg Biomembr 2011;43:587-592.
89. Shi P, Wei Y, Zhang J, Gal J, Zhu H. Mitochondrial dysfunction is a converging point of multiple pathological pathways in amyotrophic lateral sclerosis. J Alzheimers Dis 2010;20(Suppl 2):S311-S324.
90. von Lewinski F, Keller BU. Ca2+, mitochondria and selective motoneuron vulnerability: implications for ALS. Trends Neurosci 2005;28:494-500.
91. Sipe JD. Amyloidosis. Annu Rev Biochem 1992;61:947-975.
92. Chen S, Berthelier V, Hamilton JB, O'Nuallain B, Wetzel R. Amyloid-like features of polyglutamine aggregates and their assembly kinetics. Biochemistry 2002;41:7391-7399.
93. Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, Masters CL, Merlini G, Saraiva MJ, Sipe JD. Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2005;12:1-4.
94. Kyle RA. Amyloidosis: a convoluted story. Br J Haematol 2001;114:529-538.
95. Comenzo RL. Systemic immunoglobulin light-chain amyloidosis. Clin Lymphoma Myeloma 2006;7:182-185.
96. Stathopulos PB, Scholz GA, Hwang YM, Rumfeldt JA, Lepock JR, Meiering EM. Sonication of proteins causes formation of aggregates that resemble amyloid. Protein Sci 2004;13:3017-3027.
97. Chiti F, Webster P, Taddei N, Clark A, Stefani M, Ramponi G, Dobson CM. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci USA 1999;96:3590-3594.
98. Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 2006;75:333-366.
99. Antzutkin ON, Leapman RD, Balbach JJ, Tycko R. Supramolecular structural constraints on Alzheimer's beta-amyloid fibrils from electron microscopy and solid-state nuclear magnetic resonance. Biochemistry 2002;41:15436-15450.
100. Benzinger TL, Gregory DM, Burkoth TS, Miller-Auer H, Lynn DG, Botto RE, Meredith SC. Propagating structure of Alzheimer's beta-amyloid(10-35) is parallel beta-sheet with residues in exact register. Proc Natl Acad Sci USA 1998;95:13407-13412.
101. Tycko R. Solid-state NMR studies of amyloid fibril structure. Annu Rev Phys Chem 2011;62:279-299.
102. Feiner HD. Pathology of dysproteinemia: light chain amyloidosis, non-amyloid immunoglobulin deposition disease, cryoglobulinemia syndromes, and macroglobulinemia of Waldenstrom. Hum Pathol 1988;19:1255-1272.
103. Polski JM, Galvin N, Salinas-Madrigal L. Non-amyloid fibrils in heavy chain deposition disease. Kidney Int 1999;56:1601-1602.
104. Dickson DW. Discovery of new lesions in neurodegenerative diseases with monoclonal antibody techniques: is there a non-amyloid precursor to senile plaques? Am J Pathol 1997;151:7-11.
105. Lemere CA, Grenfell TJ, Selkoe DJ. The AMY antigen co-occurs with abeta and follows its deposition in the amyloid plaques of Alzheimer's disease and down syndrome. Am J Pathol 1999;155:29-37.
106. Schmidt ML, Lee VM, Forman M, Chiu TS, Trojanowski JQ. Monoclonal antibodies to a 100-kd protein reveal abundant A beta-negative plaques throughout gray matter of Alzheimer's disease brains. Am J Pathol 1997;151:69-80.
107. Chattopadhyay M, Durazo A, Sohn SH, Strong CD, Gralla EB, Whitelegge JP, Valentine JS. Initiation and elongation in fibrillation of ALS-linked superoxide dismutase. Proc Natl Acad Sci USA 2008;105:18663-18668.
108. Chattopadhyay M, Valentine JS. Aggregation of copper-zinc superoxide dismutase in familial and sporadic ALS. Antioxid Redox Signal 2009;11:1603-1614.
109. Rousseau F, Schymkowitz J, Oliveberg M. ALS precursor finally shaken into fibrils. Proc Natl Acad Sci USA 2008;105:18649-18650.
110. Fandrich M, Fletcher MA, Dobson CM. Amyloid fibrils from muscle myoglobin. Nature 2001;410:165-166.
111. Kerman A, Liu HN, Croul S, Bilbao J, Rogaeva E, Zinman L, Robertson J, Chakrabartty A. Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form. Acta Neuropathol 2010;119:335-344.
112. Kerman A, Chakrabartty A. Protein misfolding and toxicity in amyotrophic lateral sclerosis. In: Rahimi F, Bitan G, editors. Non-fibrillar amyloidogenic protein assemblies-common cytotoxins underlying degenerative diseases. Dordrecht, The Netherlands: Springer; 2012. pp 257-288.
113. Kato S, Takikawa M, Nakashima K, Hirano A, Cleveland DW, Kusaka H, Shibata N, Kato M, Nakano I, Ohama E. New consensus research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) gene mutations: inclusions containing SOD1 in neurons and astrocytes. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:163-184.
114. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006;351:602-611.
115. Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, Kwong LK, Forman MS, Ravits J, Stewart H, Eisen A, McClusky L, Kretzschmar HA, Monoranu CM, Highley JR, Kirby J, Siddique T, Shaw PJ, Lee VM, Trojanowski JQ. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007;61:427-434.
116. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130-133.
117. Tan CF, Eguchi H, Tagawa A, Onodera O, Iwasaki T, Tsujino A, Nishizawa M, Kakita A, Takahashi H. TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol 2007;113:535-542.
118. Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, Kinoshita Y, Kamada M, Nodera H, Suzuki H, Komure O, Matsuura S, Kobatake K, Morimoto N, Abe K, Suzuki N, Aoki M, Kawata A, Hirai T, Kato T, Ogasawara K, Hirano A, Takumi T, Kusaka H, Hagiwara K, Kaji R, Kawakami H. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010;465:223-226.
119. Hortobagyi T, Troakes C, Nishimura AL, Vance C, van Swieten JC, Seelaar H, King A, Al-Sarraj S, Rogelj B, Shaw CE. Optineurin inclusions occur in a minority of TDP-43 positive ALS and FTLD-TDP cases and are rarely observed in other neurodegenerative disorders. Acta Neuropathol 2011;121:519-527.
120. Ito H, Fujita K, Nakamura M, Wate R, Kaneko S, Sasaki S, Yamane K, Suzuki N, Aoki M, Shibata N, Togashi S, Kawata A, Mochizuki Y, Mizutani T, Maruyama H, Hirano A, Takahashi R, Kawakami H, Kusaka H. Optineurin is co-localized with FUS in basophilic inclusions of ALS with FUS mutation and in basophilic inclusion body disease. Acta Neuropathol 2011;121:555-557.
121. van Blitterswijk M, van Vught PW, van Es MA, Schelhaas HJ, van der Kooi AJ, de Visser M, Veldink JH, van den Berg LH. Novel optineurin mutations in sporadic amyotrophic lateral sclerosis patients. Neurobiol Aging 2012;33:1016.e1-1016.e7.
122. Kwiatkowski TJ, Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, Valdmanis P, Rouleau GA, Hosler BA, Cortelli P, de Jong PJ, Yoshinaga Y, Haines JL, Pericak-Vance MA, Yan J, Ticozzi N, Siddique T, McKenna-Yasek D, Sapp PC, Horvitz HR, Landers JE, Brown RH, Jr. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009;323:1205-1208.
123. Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P, Ganesalingam J, Williams KL, Tripathi V, Al-Saraj S, Al-Chalabi A, Leigh PN, Blair IP, Nicholson G, de Belleroche J, Gallo JM, Miller CC, Shaw CE. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009;323:1208-1211.
124. Udan M, Baloh RH. Implications of the prion-related Q/N domains in TDP-43 and FUS. Prion 2011;5:1-5.
125. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, Rahmani Z, Krizus A, McKenna-Yasek D, Cayabyab A, Gaston SM, Berger R, Tanzi RE, Halperin JJ, Herzfeldt B, Van Den Bergh R, Hung W, Bird T, Deng G, Mulder DW, Smyth C, Laing NG, Soriano E, Pericak-Vance MA, Haines J, Rouleau GA, Gusella JS, Horvitz HR, Brown RH, Jr. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62.
126. Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, Ohama E, Reaume AG, Scott RW, Cleveland DW. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998;281:1851-1854.
127. Okado-Matsumoto A, Myint T, Fujii J, Taniguchi N. Gain in functions of mutant Cu, Zn-superoxide dismutases as a causative factor in familial amyotrophic lateral sclerosis: less reactive oxidant formation but high spontaneous aggregation and precipitation. Free Radic Res 2000;33:65-73.
128. Robinson JL, Geser F, Stieber A, Umoh M, Kwong LK, Van Deerlin VM, Lee VM, Trojanowski JQ. TDP-43 skeins show properties of amyloid in a subset of ALS cases. Acta Neuropathol 2013;125:121-131.
129. LeVine H, 3rd. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 1993;2:404-410.
130. Rowland LP. How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot. Arch Neurol 2001;58:512-515.
131. Charcot J-M. De la sclérose latérale amyotrophique: symptomatologie. Le Progrès Méd 1874;2:453-455.
132. Goetz CG. Amyotrophic lateral sclerosis: early contributions of Jean-Martin Charcot. Muscle Nerve 2000;23:336-343.
133. Lillo P, Savage S, Mioshi E, Kiernan MC, Hodges JR. Amyotrophic lateral sclerosis and frontotemporal dementia: a behavioural and cognitive continuum. Amyotroph Lateral Scler 2012;13:102-109.
134. Ringholz GM, Greene SR. The relationship between amyotrophic lateral sclerosis and frontotemporal dementia. Curr Neurol Neurosci Rep 2006;6:387-392.
135. Sanelli T, Robertson J, Chakrabartty A, Strong MJ. Amyotrophic lateral sclerosis (motor neuron disease). In: Smith HJ, Simons C, Sewell RDE, editors. Protein misfolding in neurodegenerative diseases. Boca Raton, FL: CRC Press; 2008. pp 479-514.
136. Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol 2011;7:603-615.
137. Alonso A, Logroscino G, Jick SS, Hernan MA. Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. Eur J Neurol 2009;16:745-751.
138. Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol 2011;7:639-649.
139. Charcot J-M. Sclérose des cordons latéraux de la moëlle épinière chez une femme hystérique atteinte de contracture permanente des quatre membres. Bull Mem Soc Med Hop Paris 1865:24-35.
140. Charcot J-M. Deux cas d'atrophie musculaire progressive avec lésions de la substance grise et de faisceaux antérolatéraux de la moelle épinière. Arch Physiol Norm Pathol 1869;2:744-757.
141. Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology 2009;73:805-811.
142. Kuwabara S, Yokota T. Propagation: prion-like mechanisms can explain spreading of motor neuronal death in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry 2011;82:1181-1182.
143. Guest WC, Silverman JM, Pokrishevsky E, O'Neill MA, Grad LI, Cashman NR. Generalization of the prion hypothesis to other neurodegenerative diseases: an imperfect fit. J Toxicol Environ Health A 2011;74:1433-1459.
144. Prusiner SB. Cell biology. A unifying role for prions in neurodegenerative diseases. Science 2012;336:1511-1513.
145. McCord JM, Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem 1969;244:6049-6055.
146. ALSoD: the amyotrophic lateral sclerosis online genetics database. 2012. Accessed on 7 March 2012. Available from: http://alsod.iop.kcl.ac.uk/index.aspx.
147. Borchelt DR, Lee MK, Slunt HS, Guarnieri M, Xu ZS, Wong PC, Brown RH, Jr, Price DL, Sisodia SS, Cleveland DW. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc Natl Acad Sci USA 1994;91:8292-8296.
148. Reaume AG, Elliott JL, Hoffman EK, Kowall NW, Ferrante RJ, Siwek DF, Wilcox HM, Flood DG, Beal MF, Brown RH, Jr, Scott RW, Snider WD. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet 1996;13:43-47.
149. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, Chen W, Zhai P, Sufit RL, Siddique T. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994;264:1772-1775.
150. Bruijn LI, Becher MW, Lee MK, Anderson KL, Jenkins NA, Copeland NG, Sisodia SS, Rothstein JD, Borchelt DR, Price DL, Cleveland DW. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997;18:327-338.
151. Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, Sisodia SS, Cleveland DW, Price DL. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995;14:1105-1116.
152. Crow JP, Sampson JB, Zhuang Y, Thompson JA, Beckman JS. Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite. J Neurochem 1997;69:1936-1944.
153. Estevez AG, Crow JP, Sampson JB, Reiter C, Zhuang Y, Richardson GJ, Tarpey MM, Barbeito L, Beckman JS. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science 1999;286:2498-2500.
154. Wang J, Slunt H, Gonzales V, Fromholt D, Coonfield M, Copeland NG, Jenkins NA, Borchelt DR. Copper-binding-site-null SOD1 causes ALS in transgenic mice: aggregates of non-native SOD1 delineate a common feature. Hum Mol Genet 2003;12:2753-2764.
155. DiDonato M, Craig L, Huff ME, Thayer MM, Cardoso RM, Kassmann CJ, Lo TP, Bruns CK, Powers ET, Kelly JW, Getzoff ED, Tainer JA. ALS mutants of human superoxide dismutase form fibrous aggregates via framework destabilization. J Mol Biol 2003;332:601-615.
156. Roberts VA, Fisher CL, Redford SM, McRee DE, Parge HE, Getzoff ED, Tainer JA. Mechanism and atomic structure of superoxide dismutase. Free Radic Res Commun 1991;12-13:269-278.
157. Richardson JS, Richardson DC, Thomas KA, Silverton EW, Davies DR. Similarity of three-dimensional structure between the immunoglobulin domain and the copper, zinc superoxide dismutase subunit. J Mol Biol 1976;102:221-235.
158. Stevens FJ. Homology versus analogy: possible evolutionary relationship of immunoglobulins, cupredoxins, and Cu, Zn-superoxide dismutase. J Mol Recognit 2008;21:20-29.
159. Tainer JA, Getzoff ED, Beem KM, Richardson JS, Richardson DC. Determination and analysis of the 2 A-structure of copper, zinc superoxide dismutase. J Mol Biol 1982;160:181-217.
160. Roberts BR, Tainer JA, Getzoff ED, Malencik DA, Anderson SR, Bomben VC, Meyers KR, Karplus PA, Beckman JS. Structural characterization of zinc-deficient human superoxide dismutase and implications for ALS. J Mol Biol 2007;373:877-890.
161. Banci L, Benedetto M, Bertini I, Del Conte R, Piccioli M, Viezzoli MS. Solution structure of reduced monomeric Q133M2 copper, zinc superoxide dismutase (SOD). Why is SOD a dimeric enzyme? Biochemistry 1998;37:11780-11791.
162. Mulligan VK, Kerman A, Ho S, Chakrabartty A. Denaturational stress induces formation of zinc-deficient monomers of Cu, Zn superoxide dismutase: implications for pathogenesis in amyotrophic lateral sclerosis. J Mol Biol 2008;383:424-436.
163. Rumfeldt JA, Stathopulos PB, Chakrabarrty A, Lepock JR, Meiering EM. Mechanism and thermodynamics of guanidinium chloride-induced denaturation of ALS-associated mutant Cu, Zn superoxide dismutases. J Mol Biol 2006;355:106-123.
164. Redler RL, Wilcox KC, Proctor EA, Fee L, Caplow M, Dokholyan NV. Glutathionylation at Cys-111 induces dissociation of wild type and FALS mutant SOD1 dimers. Biochemistry 2011;50:7057-7066.
165. Wilcox KC, Zhou L, Jordon JK, Huang Y, Yu Y, Redler RL, Chen X, Caplow M, Dokholyan NV. Modifications of superoxide dismutase (SOD1) in human erythrocytes: a possible role in amyotrophic lateral sclerosis. J Biol Chem 2009;284:13940-13947.
166. Calabrese L, Federici G, Bannister WH, Bannister JV, Rotilio G, Finazzi-Agro A. Labile sulfur in human Superoxide dismutase. Eur J Biochem 1975;56:305-309.
167. de Beus MD, Chung J, Colon W. Modification of cysteine 111 in Cu/Zn superoxide dismutase results in altered spectroscopic and biophysical properties. Protein Sci 2004;13:1347-1355.
168. You Z, Cao X, Taylor AB, Hart PJ, Levine RL. Characterization of a covalent polysulfane bridge in copper-zinc superoxide dismutase. Biochemistry 2010;49:1191-1198.
169. Mulligan VK, Hadley KC, Chakrabartty A. Analyzing complicated protein folding kinetics rapidly by analytical Laplace inversion using a Tikhonov regularization variant. Anal Biochem 2012;421:181-190.
170. Okado-Matsumoto A, Guan Z, Fridovich I. Modification of cysteine 111 in human Cu, Zn-superoxide dismutase. Free Radic Biol Med 2006;41:1837-1846.
171. Carrico RJ, Deutsch HF. Isolation of human hepatocuprein and cerebrocuprein. Their identity with erythrocuprein. J Biol Chem 1969;244:6087-6093.
172. Bannister WH, Dalgleish DG, Bannister JV, Wood EJ. Physiochemical and spectroscopic properties of human erythrocyte cupro-zinc protein (erythrocuprein). Int J Biochem 1972;3:560-568.
173. Lepock JR, Frey HE, Hallewell RA. Contribution of conformational stability and reversibility of unfolding to the increased thermostability of human and bovine superoxide dismutase mutated at free cysteines. J Biol Chem 1990;265:21612-21618.
174. Stathopulos PB, Rumfeldt JA, Scholz GA, Irani RA, Frey HE, Hallewell RA, Lepock JR, Meiering EM. Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis show enhanced formation of aggregates in vitro. Proc Natl Acad Sci USA 2003;100:7021-7026.
175. Biliaderis CG, Weselake RJ, Petkau A, Friesen AD. A calorimetric study of human CuZn superoxide dismutase. Biochem J 1987;248:981-984.
176. Lepock JR. Measurement of protein stability and protein denaturation in cells using differential scanning calorimetry. Methods 2005;35:117-125.
177. Mei G, Rosato N, Silva N, Jr., Rusch R, Gratton E, Savini I, Finazzi-Agro A. Denaturation of human Cu/Zn superoxide dismutase by guanidine hydrochloride: a dynamic fluorescence study. Biochemistry 1992;31:7224-7230.
178. Furukawa Y, O'Halloran TV. Amyotrophic lateral sclerosis mutations have the greatest destabilizing effect on the apo- and reduced form of SOD1, leading to unfolding and oxidative aggregation. J Biol Chem 2005;280:17266-17274.
179. Stathopulos PB, Rumfeldt JA, Karbassi F, Siddall CA, Lepock JR, Meiering EM. Calorimetric analysis of thermodynamic stability and aggregation for apo and holo amyotrophic lateral sclerosis-associated Gly-93 mutants of superoxide dismutase. J Biol Chem 2006;281:6184-6193.
180. Lindberg MJ, Tibell L, Oliveberg M. Common denominator of Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis: decreased stability of the apo state. Proc Natl Acad Sci USA 2002;99:16607-16612.
181. Lynch SM, Boswell SA, Colon W. Kinetic stability of Cu/Zn superoxide dismutase is dependent on its metal ligands: implications for ALS. Biochemistry 2004;43:16525-16531.
182. Lynch SM, Colon W. Dominant role of copper in the kinetic stability of Cu/Zn superoxide dismutase. Biochem Biophys Res Commun 2006;340:457-461.
183. Kayatekin C, Zitzewitz JA, Matthews CR. Zinc binding modulates the entire folding free energy surface of human Cu, Zn superoxide dismutase. J Mol Biol 2008;384:540-555.
184. Pantoliano M, McDonnell PJ, Valentine JS. Reversible loss of metal ions from the zinc binding site of copper-zinc superoxide dismutase: the low pH transition. J Am Chem Soc 1979;101:6454-6456.
185. Pantoliano M, Valentine JS, Mammone RJ, Scholler DM. pH Dependence of metal ion binding to the native zinc site of bovine erythrocuprein (superoxide dismutase). J Am Chem Soc 1982;104:1717-1723.
186. Danielsson J, Kurnik M, Lang L, Oliveberg M. Cutting off functional loops from homodimeric enzyme superoxide dismutase 1 (SOD1) leaves monomeric beta-barrels. J Biol Chem 2011;286:33070-33083.
187. Potter SZ, Zhu H, Shaw BF, Rodriguez JA, Doucette PA, Sohn SH, Durazo A, Faull KF, Gralla EB, Nersissian AM, Valentine JS. Binding of a single zinc ion to one subunit of copper-zinc superoxide dismutase apoprotein substantially influences the structure and stability of the entire homodimeric protein. J Am Chem Soc 2007;129:4575-4583.
188. Svensson A-KE, Bilsel O, Kayatekin C, Adefusika JA, Zitzewitz JA, Matthews CR. Metal-free ALS variants of dimeric human Cu, Zn-superoxide dismutase have enhanced populations of monomeric species. PLoS One 2010;5:e10064.
189. Nakano R, Inuzuka T, Kikugawa K, Takahashi H, Sakimura K, Fujii J, Taniguchi N, Tsuji S. Instability of mutant Cu/Zn superoxide dismutase (Ala4Thr) associated with familial amyotrophic lateral sclerosis. Neurosci Lett 1996;211:129-131.
190. Watanabe Y, Kono Y, Nanba E, Ohama E, Nakashima K. Instability of expressed Cu/Zn superoxide dismutase with 2 bp deletion found in familial amyotrophic lateral sclerosis. FEBS Lett 1997;400:108-112.
191. Winterbourn CC, Domigan NM, Broom JK. Decreased thermal stability of red blood cell glu100-->gly superoxide dismutase from a family with amyotrophic lateral sclerosis. FEBS Lett 1995;368:449-451.
192. Cardoso RM, Thayer MM, DiDonato M, Lo TP, Bruns CK, Getzoff ED, Tainer JA. Insights into Lou Gehrig's disease from the structure and instability of the A4V mutant of human Cu, Zn superoxide dismutase. J Mol Biol 2002;324:247-256.
193. Shaw BF, Valentine JS. How do ALS-associated mutations in superoxide dismutase 1 promote aggregation of the protein? Trends Biochem Sci 2007;32:78-85.
194. Lyons TJ, Nersissian A, Huang H, Yeom H, Nishida CR, Graden JA, Gralla EB, Valentine JS. The metal binding properties of the zinc site of yeast copper-zinc superoxide dismutase: implications for amyotrophic lateral sclerosis. J Biol Inorg Chem 2000;5:189-203.
195. Nordlund A, Leinartaite L, Saraboji K, Aisenbrey C, Grobner G, Zetterstrom P, Danielsson J, Logan DT, Oliveberg M. Functional features cause misfolding of the ALS-provoking enzyme SOD1. Proc Natl Acad Sci USA 2009;106:9667-9672.
196. Kayatekin C, Zitzewitz JA, Matthews CR. Disulfide-reduced ALS variants of Cu, Zn superoxide dismutase exhibit increased populations of unfolded species. J Mol Biol 2010;398:320-331.
197. Tiwari A, Hayward LJ. Familial amyotrophic lateral sclerosis mutants of copper/zinc superoxide dismutase are susceptible to disulfide reduction. J Biol Chem 2003;278:5984-5992.
198. Hough MA, Grossmann JG, Antonyuk SV, Strange RW, Doucette PA, Rodriguez JA, Whitson LJ, Hart PJ, Hayward LJ, Valentine JS, Hasnain SS. Dimer destabilization in superoxide dismutase may result in disease-causing properties: structures of motor neuron disease mutants. Proc Natl Acad Sci USA 2004;101:5976-5981.
199. Deng HX, Hentati A, Tainer JA, Iqbal Z, Cayabyab A, Hung WY, Getzoff ED, Hu P, Herzfeldt B, Roos RP, Warner C, Deng G, Soriano E, Smyth C, Parge HE, Ahmed A, Roses AD, Hallewell RA, Pericak-Vance MA, Siddique T. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science 1993;261:1047-1051.
200. Antonyuk S, Elam JS, Hough MA, Strange RW, Doucette PA, Rodriguez JA, Hayward LJ, Valentine JS, Hart PJ, Hasnain SS. Structural consequences of the familial amyotrophic lateral sclerosis SOD1 mutant His46Arg. Protein Sci 2005;14:1201-1213.
201. Tiwari A, Hayward LJ. Mutant SOD1 instability: implications for toxicity in amyotrophic lateral sclerosis. Neurodegener Dis 2005;2:115-127.
202. Rodriguez JA, Valentine JS, Eggers DK, Roe JA, Tiwari A, Brown RH, Jr., Hayward LJ. Familial amyotrophic lateral sclerosis-associated mutations decrease the thermal stability of distinctly metallated species of human copper/zinc superoxide dismutase. J Biol Chem 2002;277:15932-15937.
203. Rodriguez JA, Shaw BF, Durazo A, Sohn SH, Doucette PA, Nersissian AM, Faull KF, Eggers DK, Tiwari A, Hayward LJ, Valentine JS. Destabilization of apoprotein is insufficient to explain Cu, Zn-superoxide dismutase-linked ALS pathogenesis. Proc Natl Acad Sci USA 2005;102:10516-10521.
204. Vassall KA, Stubbs HR, Primmer HA, Tong MS, Sullivan SM, Sobering R, Srinivasan S, Briere LA, Dunn SD, Colon W, Meiering EM. Decreased stability and increased formation of soluble aggregates by immature superoxide dismutase do not account for disease severity in ALS. Proc Natl Acad Sci USA 2011;108:2210-2215.
205. Pardo CA, Xu Z, Borchelt DR, Price DL, Sisodia SS, Cleveland DW. Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. Proc Natl Acad Sci USA 1995;92:954-958.
206. Rakhit R, Robertson J, Vande Velde C, Horne P, Ruth DM, Griffin J, Cleveland DW, Cashman NR, Chakrabartty A. An immunological epitope selective for pathological monomer-misfolded SOD1 in ALS. Nat Med 2007;13:754-759.
207. Bosco DA, LaVoie MJ, Petsko GA, Ringe D. Proteostasis and movement disorders: Parkinson's disease and amyotrophic lateral sclerosis. Cold Spring Harbor Perspect Biol 2011;3:a007500.
208. Bendotti C, Marino M, Cheroni C, Fontana E, Crippa V, Poletti A, De Biasi S. Dysfunction of constitutive and inducible ubiquitin-proteasome system in amyotrophic lateral sclerosis: implication for protein aggregation and immune response. Progr Neurobiol 2012;97:101-126.
209. Kabashi E, Durham HD. Failure of protein quality control in amyotrophic lateral sclerosis. Biochim Biophys Acta 2006;1762:1038-1050.
210. Hwang YM, Stathopulos PB, Dimmick K, Yang H, Badiei HR, Tong MS, Rumfeldt JA, Chen P, Karanassios V, Meiering EM. Non-amyloid aggregates arising from mature Cu/Zn superoxide dismutases resemble those observed in amyotrophic lateral sclerosis. J Biol Chem 2010;285:41701-41711.
211. Rakhit R, Crow JP, Lepock JR, Kondejewski LH, Cashman NR, Chakrabartty A. Monomeric Cu, Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic lateral sclerosis. J Biol Chem 2004;279:15499-15504.
212. Rakhit R, Cunningham P, Furtos-Matei A, Dahan S, Qi XF, Crow JP, Cashman NR, Kondejewski LH, Chakrabartty A. Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. J Biol Chem 2002;277:47551-47556.
213. Andrus PK, Fleck TJ, Gurney ME, Hall ED. Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 1998;71:2041-2048.
214. Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, Brown RH, Jr. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 1997;42:644-654.
215. Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U, Kowall NW, Brown RH, Jr., Beal MF. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997;69:2064-2074.
216. Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med 2010;48:629-641.
217. Poon HF, Hensley K, Thongboonkerd V, Merchant ML, Lynn BC, Pierce WM, Klein JB, Calabrese V, Butterfield DA. Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice--a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med 2005;39:453-462.
218. Shaw PJ, Eggett CJ. Molecular factors underlying selective vulnerability of motor neurons to neurodegeneration in amyotrophic lateral sclerosis. J Neurol 2000;247(Suppl 1):I17-I27.
219. Simpson EP, Yen AA, Appel SH. Oxidative stress: a common denominator in the pathogenesis of amyotrophic lateral sclerosis. Curr Opin Rheumatol 2003;15:730-736.
220. Mulligan VK, Kerman A, Laister RC, Sharda PR, Arslan PE, Chakrabartty A. Early steps in oxidation-induced SOD1 misfolding: implications for non-amyloid protein aggregation in familial ALS. J Mol Biol 2012;421:631-652.
221. Baures PW, Oza VB, Peterson SA, Kelly JW. Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid. Bioorg Med Chem 1999;7:1339-1347.
222. Baures PW, Peterson SA, Kelly JW. Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg Med Chem 1998;6:1389-1401.
223. Miroy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C, Kelly JW. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci USA 1996;93:15051-15056.
224. Oza VB, Petrassi HM, Purkey HE, Kelly JW. Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors. Bioorg Med Chem Lett 1999;9:1-6.
225. Ray SS, Nowak RJ, Brown RH, Jr., Lansbury PT, Jr .Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. Proc Natl Acad Sci USA 2005;102:3639-3644.
226. Bugyei-Twum A. Inhibition of transthyretin fibrillogenesis using a conformation specific antibody. M.Sc. Thesis. Toronto, ON: University of Toronto; 2012. pp 68.
227. Quintas A, Saraiva MJ, Brito RM. The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution. FEBS Lett 1997;418:297-300.
228. Quintas A, Saraiva MJ, Brito RM. The tetrameric protein transthyretin dissociates to a non-native monomer in solution. A novel model for amyloidogenesis. J Biol Chem 1999;274:32943-32949.
229. Quintas A, Vaz DC, Cardoso I, Saraiva MJ, Brito RM. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem 2001;276:27207-27213.
230. Lindberg MJ, Bystrom R, Boknas N, Andersen PM, Oliveberg M. Systematically perturbed folding patterns of amyotrophic lateral sclerosis (ALS)-associated SOD1 mutants. Proc Natl Acad Sci USA 2005;102:9754-9759.
231. Lindberg MJ, Normark J, Holmgren A, Oliveberg M. Folding of human superoxide dismutase: disulfide reduction prevents dimerization and produces marginally stable monomers. Proc Natl Acad Sci USA 2004;101:15893-15898.
232. Nordlund A, Oliveberg M. Folding of Cu/Zn superoxide dismutase suggests structural hotspots for gain of neurotoxic function in ALS: parallels to precursors in amyloid disease. Proc Natl Acad Sci USA 2006;103:10218-10223.
233. Svensson A-KE, Bilsel O, Kondrashkina E, Zitzewitz JA, Matthews CR. Mapping the folding free energy surface for metal-free human Cu, Zn superoxide dismutase. J Mol Biol 2006;364:1084-1102.
234. Vassall KA, Stathopulos PB, Rumfeldt JA, Lepock JR, Meiering EM. Equilibrium thermodynamic analysis of amyotrophic lateral sclerosis-associated mutant apo Cu, Zn superoxide dismutases. Biochemistry 2006;45:7366-7379.
235. Silva N, Jr., Gratton E, Mei G, Rosato N, Rusch R, Finazzi-Agro A. Molten globule monomers in human superoxide dismutase. Biophys Chem 1993;48:171-182.
236. Khare SD, Caplow M, Dokholyan NV. The rate and equilibrium constants for a multistep reaction sequence for the aggregation of superoxide dismutase in amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2004;101:15094-15099.
237. Rumfeldt JA, Lepock JR, Meiering EM. Unfolding and folding kinetics of amyotrophic lateral sclerosis-associated mutant Cu, Zn superoxide dismutases. J Mol Biol 2009;385:278-298.
238. Ip P, Mulligan VK, Chakrabartty A. ALS-causing SOD1 mutations promote production of copper-deficient misfolded species. J Mol Biol 2011;409:839-852.
239. Banci L, Bertini I, Boca M, Calderone V, Cantini F, Girotto S, Vieru M. Structural and dynamic aspects related to oligomerization of apo SOD1 and its mutants. Proc Natl Acad Sci USA 2009;106:6980-6985.
240. Ding F, Furukawa Y, Nukina N, Dokholyan NV. Local unfolding of Cu, Zn superoxide dismutase monomer determines the morphology of fibrillar aggregates. J Mol Biol 2012;421:548-560.
241. Hu J, Chen K, Ni B, Li L, Chen G, Shi S. A novel SOD1 mutation in amyotrophic lateral sclerosis with a distinct clinical phenotype. Amyotroph Lateral Scler 2012;13:149-154.